ctDNA monitoring shows promise but faces genomic hurdles in sarcoma subtypes

The study reports on the evolving clinical utility of circulating tumor DNA (ctDNA) across multiple sarcoma subtypes, including gastrointestinal stromal tumor, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma. Investigators note that while technical advances have improved rare ctDNA detection in other cancers, sarcoma genomic complexity and heterogeneity continue to pose significant analytical challenges. The review outlines current evidence for ctDNA applications in monitoring recurrence and guiding therapy, emphasizing that standardized analytical workflows and rigorous validation will be required before liquid biopsy can be integrated into routine sarcoma diagnostics.